Smartening Africa’s Drug Supply Chain with IBM AI

By Crystal Lubbe

November 27, 2024

The article from Bizcommunity titled “African Drug Supply Chain Gets Smarter with IBM-Powered AI Platform” highlights a major initiative aimed at enhancing the pharmaceutical supply chain in Africa through the use of advanced technologies, focusing on AI and digital solutions. This initiative revolves around the establishment of the Pulse platform by NABP, designed to improve efficiency and transparency within the African drug supply chain.

Collaboration and Partnerships

This initiative involves a collaboration between Prosper Africa, USAID’s e-Trade Alliance, IBM Consulting, and the National Association of Boards of Pharmacy (NABP) to launch a platform called Pulse by NABP in South Africa. This partnership aims to connect US and global pharmaceutical companies like Pfizer and Roche with African distributors and pharmacies, proving critical in strengthening the African drug supply chain.

Use of AI and Digital Solutions

The Pulse platform leverages IBM’s Watson AI capabilities to enhance the traceability of drugs exported to Africa. This initiative not only improves supply chain visibility but also reduces spoilage, ensuring consistent stock levels. Furthermore, it fosters profitable partnerships with international suppliers. IBM Consulting will utilize its AI-powered delivery platform, IBM Consulting Advantage, to collect and analyse product scan data, enabling pharmacies and retailers to make more informed, data-driven decisions. Ultimately, this enhances the African drug supply chain.

Market Opportunities and Challenges

The African pharmaceutical market, valued at $26.85 billion in 2023, is projected to grow 3.4% annually from 2024 to 2030. However, fragmented supply chains, poor infrastructure, and diverse regulations hinder efficient pharmaceutical distribution across African countries. These challenges result in supply inefficiencies, limited product availability, and higher patient costs, complicating efforts to improve the drug supply chain.

Benefits of the Platform

Enhanced Traceability: The platform improves the ability to identify and trace medications, ensuring greater security in the drug supply chain.
Inventory Optimization: AI tools help minimise stockouts and overstock situations by optimising inventory levels.
Improved Operations: The platform enhances operations for African distributors and pharmacies, leading to more efficient and profitable supply chains.
Economic and Social Impact: This initiative enhances economic growth and health by improving supply chain visibility and creating a transparent, accessible medication market.

Training and Capacity Building

IBM will offer training on AI tools like Watsonx.ai to help African pharmacies and retailers utilise data-driven decision-making effectively. This training is part of a broader strategy to build resilient ecosystems that drive economic growth and societal impact.

Public-Private Collaboration

Altogether, collaboration between public and private entities undoubtedly reflects the potential to drive both economic growth and health improvements. Furthermore, emphasises the use of technology and expertise to enhance transparency and foster trust in vital industries like healthcare.

The Pulse by NABP, powered by IBM AI, addresses Africa’s pharmaceutical supply chain challenges through traceability and operational efficiency.
This initiative benefits US companies and African consumers by improving medication access and strengthening the African drug supply chain.

Reference url

Recent Posts

Biosimilars Market Trends 2025: Understanding Erosion and Growth

By Rene Pretorius

September 26, 2025

This article explores how biosimilars market trends are transforming the biologics market, making treatments more affordable and reshaping competition. Drawing from a 2022 comparative analysis of US, Germany, and Switzerland markets (2011–2020) [1] and updated 2024–2025 data [2-4] it...
Addressing GLP-1 Access Inequity: Lessons from HIV/AIDS Mobilization

By João L. Carapinha

September 19, 2025

The BMJ article by Ratevosian and Sturchio asserts that GLP-1 access inequity is becoming emblematic of global health disparity. This is driven by high costs and limited availability, particularly in low- and middle-income countries. Drawing lessons from the global mobilization that expanded acce...
CAPVAXIVE Pneumococcal Vaccine Delivers Strong Immune Response in At-Risk Youth

By HEOR Staff Writer

September 17, 2025

What makes the CAPVAXIVE pneumococcal vaccine significant for children and adolescents at higher risk for pneumococcal disease? The CAPVAXIVE pneumococcal vaccine (21-valent conjugate vaccine) demonstrated robust immune responses and broad serotype coverage in Merck’s Phase 3 STRIDE-13 trial. ...